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Abstract
Background: Colorectal cancer is a common disease that involves genetic alterations, such as inactivation of
tumour suppressor genes and activation of oncogenes. Among them are RAS and BRAF mutations, which rarely
coexist in the same tumour. Individual members of the Rho (Ras homology) GTPases contribute with distinct
roles in tumour cell morphology, invasion and metastasis. The aim of this study is to dissect cell migration and
invasion pathways that are utilised by BRAF
V600E as compared to KRAS
G12V and HRAS
G12V oncoproteins. In
particular, the role of RhoA (Ras homolog gene family, member A), Rac1 (Ras-related C3 botulinum toxin
substrate 1) and Cdc42 (cell division cycle 42) in cancer progression induced by each of the three oncogenes is
described.
Methods: Colon adenocarcinoma cells with endogenous as well as ectopically expressed or silenced oncogenic
mutations of BRAF
V600E, KRAS
G12V and HRAS
G12V were employed. Signalling pathways and Rho GTPases were
inhibited with specific kinase inhibitors and siRNAs. Cell motility and invasion properties were correlated with
cytoskeletal properties and Rho GTPase activities.
Results: Evidence presented here indicate that BRAF
V600E significantly induces cell migration and invasion
properties in vitro in colon cancer cells, at least in part through activation of RhoA GTPase. The relationship
established between BRAF
V600E and RhoA activation is mediated by the MEK-ERK pathway. In parallel,
KRAS
G12V enhances the ability of colon adenocarcinoma cells Caco-2 to migrate and invade through filopodia
formation and PI3K-dependent Cdc42 activation. Ultimately increased cell migration and invasion, mediated
by Rac1, along with the mesenchymal morphology obtained through the Epithelial-Mesenchymal Transition
(EMT) were the main characteristics rendered by HRAS
G12V in Caco-2 cells. Moreover, BRAF and KRAS
oncogenes are shown to cooperate with the TGFb-1 pathway to provide cells with additional transforming
properties.
Conclusion: This study discriminates oncogene-specific cell migration and invasion pathways mediated by Rho
GTPases in colon cancer cells and reveals potential new oncogene-specific characteristics for targeted therapeutics.
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Colorectal cancer represents a complex disease that
involves multiple steps of genetic alterations, like inactiva-
tion of tumour suppressor genes and activation of onco-
genes, often associated with progression from
premalignant lesion (adenoma) to invasive adenocarci-
noma [1]. KRAS mutations have been found in about
35% of colon carcinomas that mainly occur at codons 12,
13 and 61, resulting in a constitutively active form of
KRAS GTPase. Consequently, multiple RAS effector
pathways that regulate fundamental biological processes
such as proliferation, apoptosis, and cell motility, become
activated and/or deregulated. More specifically, mutant
KRAS disrupts actin cytoskeleton and maintains motility
in colon cancer cells [2]. Likewise, BRAF, a major down-
stream effector of KRAS, is also considered an oncogene
whose activating mutations appear in 70% of human
malignant melanomas and in about 12-18% of human
colon cancers. The most frequent BRAF mutation is at
codon 600 that results in elevated kinase activity [3,4].
Mutant BRAF may also interfere with organization of
cytoskeleton and affect cell migration and invasion ability
[5].
Key steps in invasion and metastasis are tightly regu-
lated or influenced by the Rho family GTPases, which
may include alterations in cell adhesion, cell-matrix,
cell-cell interactions and actin organization, ultimately
leading to the acquisition of an invasive phenotype.
Many studies have investigated the role of Rho GTPases
in tumour progression showing their contribution in
cancer initiation and progression, through the acquisi-
tion of uncontrolled proliferation, survival and escape
from apoptosis as well as tissue invasion and the estab-
lishment of metastasis [6]. Unlike KRAS and BRAF,
mutations in RHO genes are extremely rare in tumours,
but their expression and/or activity is frequently altered
in a variety of human cancers. RhoA is frequently over-
expressed in cancer [7], while depletion of Rac1 strongly
inhibits lamellipodia formation, cell migration and inva-
sion in carcinoma cells [8]. Another Rho family gene,
Cdc42 is also important for cell motility and able to
induce a mesenchymal-amoeboid transition in mela-
noma cells [9,10]. Regulation of Rho GTPases is exten-
sively studied and it is well known that extracellular
signal-regulated kinase (ERK) signaling is important for
cell motility through Rho GTPases [2,11]. PI3K pathway
is also involved in Rho family signal transduction and
affects properties like cell migration [12,13]. Although a
significant number of studies have analysed the role of
Rho pathways in RAS-induced transformation, very little
is known about the differential regulation of Rho
GTPases by RAS and BRAF oncogene, as well as their
subsequent contribution in oncogene-specific cell migra-
tion properties.
In order to invade into other tissues, epithelial cancer
cells must disrupt the integrity of epithelium and base-
ment membrane to enter the underlying stroma. This
normally requires acquisition of a migratory phenotype,
a process frequently referred as epithelial to mesenchy-
mal transition (EMT). Invasive epithelial cancer cells
often show reduced expression of E-cadherin, a cell-cell
adhesion protein, and an increased expression of
mesenchymal markers, such as vimentin and N-cadherin
[14]. It has been shown that oncogenic HRAS is
required for both induction and maintenance of EMT,
mainly through its downstream effector ERK [15,16]. A
representative model for studying EMT has been devel-
oped in our lab following stable transfection HRAS
G12V
in colon adenocarcinoma Caco-2 cells (Caco-H cells).
The transformation process rendered mesenchymal-like
characteristics to the cells as determined by their mor-
phology and global gene expression profile analysis
[16,17].
Many regulators and effectors have been described for
the Rho family GTPases that may be implicated in their
functions, including Focal Adhesion Kinase (FAK), a
protein known to contribute to EMT, and fascin that is
mainly involved with actin cytoskeletal organization as
well as cell migration, downstream of Rho GTPases
[18]. Fascin is an actin-bundling protein normally upre-
gulated in several epithelial neoplasms and may have
prognostic value as an early biomarker for more aggres-
sive colorectal adenocarcinomas, since it contributes to
cancer cell migration in vitro and metastasis in vivo
[19,20].
Since KRAS
G12V and BRAF
V600E mutations rarely
coexist in human tumours, we aim to study their inde-
pendent and comparative contribution in migration and
invasion of colorectal cancer cells through Rho GTPases
signalling. Towards this end Caco-2 cells, that represent
an intermediate adenoma of human colorectal cancer,
were stably transfected to ectopically express KRAS
G12V
(Caco-K cells) and BRAF
V600E (Caco-BR cells) [21]. The
doubling time and the cell cycle distribution by means
of flow cytometry for each cell line have been examined.
Results obtained indicated Caco-BR cells to have
acquired a higher proliferation rate as compared to the
parental cell line, Caco-2. For determining the “transfor-
mation potential”, a number of cell properties were ana-
lyzed following stable transfection. BRAF
V600E induced
cell properties, included altered morphology, colony for-
mation ability in soft agar, tumorigenicity in SCID mice
[21]. Here, we present evidence that BRAF
V600E
enhances migration and invasion properties in colon
carcinoma cells through RhoA activation, while
KRAS
G12V induces these properties less efficiently as
compared to BRAF
V600E, albeit through Cdc42 activation
and filopodia formation. In parallel, HRAS
G12V induces
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results indicate that although KRAS and BRAF are
members of the same pathway, different Rho-dependent
mechanisms are utilised by each oncogene to transform
colon cancer cells. These findings could be exploited
towards targeted therapies to Rho pathway components
depending on the genetic background of the cancer
patient.
Materials and methods
Cell culture
Caco-2, HT29 and DLD-1 human colon adenoma-carci-
noma cell lines were obtained from American Type Cul-
ture Collection (ATCC) and DKO-4 cells were kindly
provided by Drs T. Sasazuki and S. Shirasawa. Onco-
genic models used in the present study were generated
in Caco-2 cells by stable transfection in order to consti-
tutively express HRAS
G12V (Caco-H), KRAS
G12V (Caco-
K) or BRAF
V600E (Caco-BR) oncogenes and have been
previously described [13,18]. In short, pcDNA3-
KRAS
G12V, pcDNA3-HRAS
G12V or pH8-BRAF
V600E plas-
mids were transfected into Caco-2 cells using the Ca3
(PO4)2 precipitation technique and individual clones
were selected with 0.5 mg/ml Geneticin (Sigma-Aldrigh,
Poole, UK). All cell lines used in this study were grown
in D-MEM medium supplemented with 10% FBS, anti-
biotics and amino acids. Caco-K6 and Caco-K15 clones
were selected to overexpress KRAS
G12V, Caco-H2 clones
for overexpressing HRAS
G12V and Caco-BR13 and
Caco-BR23 for overexpressing BRAF
V600E in Caco-2
cells. Since Caco-BR13 share similar properties with
Caco-BR23 and likewise Caco-K6 are similar to Caco-
K15, in some experiments data are presented only for
Caco-BR13 and Caco-K15. In such cases the clones are
named as Caco-BR and Caco-K respectively.
Protein kinase inhibitors
Cells were treated with MEK inhibitor UO126 (Alexis
Biochemicals, CA) to block MEK-ERK pathway. Wort-
manin (Alexis Biochemical) was used to block PI3K
pathway and for inhibition of RhoA/Rho kinase pathway
the specific inhibitor Y-27632 (Sigma) was used.
NSC23766 (Calbiochem, Gibbstown, US) was used to
block Rac1 GTPase.
Suppression of BRAF
V600E expression by RNA interference
HT29 cells were selected because of their BRAF
V600E
mutation. The small inhibitory duplex shRNA oligo was
cloned into the HindIII and BglII sites in pSUPER (Oli-
goengine, Seattle, WA). The sense strand of the shRNA
pSUPER BRAF
V600E insert was BRAFmutshRNA:
gatccccGCTACAGAGAAATCTCGAT-ttcaagagaATC-
GAGATTTCTCTGTAGCtttttggaaa {Hingorani, 2003 2/
id}. HT29 cells were also transfected with the empty
vector (pSUPER using the CaPO4 precipitation techni-
que and selected with Geneticin (Invitrogen). The
names of clones used in this study are: HTps (for empty
vector) and HTshBR3 (for BRAF
V600E silencing).
Western Blotting and GST pull-down assay
Whole cell lysates were prepared with lysis buffer con-
taining 50 mM Tris-HCl (pH 7.4), 0,5% sodium deoxy-
cholate, 0,1% sodium dodecyl sulfate (SDS), 500 mM
NaCl, 10 mM MgCl2, 1% (v/v) Triton X-100, 1 mM
sodium orthovanadate, 10 μg/ml aprotinin, 10 μg/ml
leupeptin and 0.2 mM phenylmethylsulfonyl fluoride
(PMSF). For Western blotting, protein concentrations
were determined by the Bradford assay (Bio-Rad Labora-
tories, Hercules, CA) using bovine serum albumin as a
standard. Extracts were resolved on SDS-PAGE (10% or
12% w/v acrylamide), transferred to nitrocellulose mem-
brane (Whatman, Scheicher & Schuell, Dassel, Ger-
many). Membranes were blocked with 5% milk in TBST
for one hour and incubated with the specific antibodies
overnight at 4°C, washed and incubated with the appro-
priate secondary antibody, for 1 hour at room tempera-
ture. Antibodies used were against: RhoA (sc-418),
cdc42 (sc-87), Tubulin (sc-8035), Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (sc-47724), ERK2
(sc-1647), p-Cofilin (hSer 3) (sc-12912-R), Vimentin (sc-
6260), E-cadherin (sc-7870), N-cadherin (sc-7939) and
p-Myl (sc-12896-R) purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA), Rac1 (05-389), FAK (05-537)
purchased from Upstate (Lake Placid, NY, USA),
pSer
445B-Raf (2696) purchased from Cell Signalling
(Danvers, MA, USA) and anti-fascin was a kind gift
from Prof. Erik Langhoff. Antibody signal was obtained
with the enhanced chemiluminescence plus Western
blotting detection system (Amersham Biosciences,
Uppsala, Sweden) after exposure to Kodak Super RX
film. Values were measured using the Image-Quant soft-
ware (Amersham Biosciences) and protein levels were
normalized against tubulin.
For Rac1-GTP and cdc42-GTP GST pull-down assay,
cells were cultured in 10 cm petri dish and cell lysates
were prepared with lysis buffer used for western blot-
ting. 500 μg of the identical protein extract were incu-
bated with GST-PAK (p21-activated kinase) to
glutathione agarose beads for 1 hour by rotating at 4°C
and beads were washed 4 times in wash buffer (50 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM MgCl2,1 %
(v/v) Triton X-100, 1 mM dithiothreitol (DTT), 10 μg/
ml aprotinin, 10 μg/ml leupeptin and 0.2 mM PMSF).
For RhoA-GTP GST pull-down assay it was used the
Rho Assay Reagent [Rho-binding domain (RBD) of Rho-
tekin, agarose] from Upstate. All the experiments were
repeated at least three times and representative images
are shown.
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Cells were grown on coverslips in 24-well plates and
fixed using 4% paraformaldehyde (PFH) in PBS for 10
minutes at room temperature or cold methanol/acetone
(8:1) for 10 minutes at -20°C. Cells that were fixed PFH
were permeabilized with 0.1% Triton X-100 for 10 min-
utes shaking at room temperature. Cells were blocked
with 4% fetal bovine serum (FBS) in phosphate-buffered
saline (PBS) at room temperature for 1 hour and stained
with the primary antibodies overnight at 4°C. Secondary
antibodies Alexa Fluor 488 goat anti-mouse (A11001) or
anti-rabbit (A11008) (Molecular Probes, Eugene, OR,
USA) were applied to the cells for 1 hour at room tem-
perature. For actin cytoskeleton staining cells were fixed
with PFH, permeabilized and incubated with Alexa fluor
phalloidin (A22283, Molecular Probes, Invitrogen).
Nuclei were stained with Hoechst No. 33342 (Sigma,
B2261) for 10 minutes at room temperature, coverslips
were mounted on glass slides in Gelvatol/DABCO aqu-
eous medium (Sigma-Aldrigh, Poole, UK) and visualized
with a Leica TCS SPE confocal laser scanning micro-
scope. LAS AF software was used for image acquisition
(Leica Lasertechnik, Heidelberg, Germany).
RNA Extraction/Reverse Transcription and Real Time-PCR
Total RNA isolation from cultured cells was performed
using the Trizol reagent (Invitrogen, Karlsruhe, Ger-
many). Reverse transcription was carried out from 3.0
μg of purified RNA using the SuperScript Reverse Tran-
scriptase (Invitrogen, Karlsruhe, Germany) following the
manufacturer’s instructions.
Real-time quantification at the mRNA level was car-
ried out in 96-well PCR plates using a Bio-Rad iCycler
and the iQ5 Multicolor real-Time PCR detection system
(Bio-Rad, Hercules CA, USA). Each reaction contained 1
× iQ SYBR Green Supermix (Bio-Rad, Hercules CA,
USA) and 150 nmol/L of each primer. All genes were
tested in triplicates. Results were analyzed on the iCycler
s o f t w a r e .V a l u e sw e r en o r m a l i z e dt oG A P D H .P r i m e r s
used were the following: glyceraldehyde-3-phosphate
dehydrogenase (GAPDH): GAAGGTGAAGGTCG-
GAGT (Fw) and CATGGGTGGAATCATATTGGAA
(Rv), E-cadherin: GAACAGCACGTACACAGCCCT
(Fw) and GCAGAAGTTCCCTGTTCCAG (Rv). Ν-cad-
herin: (Fw) TATATGCCCAAGACAAAGAGAC and
TTCTGCTGACTCCTTCACTG (Rv), Vimentin:
CTCGGTGGACTTCTCGCTGGCC (Fw) and TCCTGC
AGGTTCTTGGCAGCC (Rv).
Transwell Assays for Cellular Migration, Invasion and
wound healing
For migration study, cells were trypsinised, washed
thrice in medium with 1% FBS, and counted with a Z2
Coulter Counter (Beckman Coulter). Cells (1 × 10
4)
were plated into the upper chamber of 8 μm-pore
Transwell filter (Corning) mounted in a 24-well dish
with the lower chamber containing medium with 10%
FBS. Before use, filters were pre-coated for 10 hours at
4°C with fibronectin (10 μg/ml; Sigma- Aldrich) and
washed thrice. Cells were allowed to migrate in 5% CO2
for 30-36 hours at 37°C, fixed with methanol for 10
minutes at room temperature and stained with 0.1%
crystal violet. The underside of the filters was examined
with a 40 × objective of a Nikon Eclipse T-200 (Tokyo,
Japan) inverted phase-contrast microscope and number
of migrating cells was determined for each well. For cell
invasion assay, the procedure was the same with the
modification that the upper chamber was coated with
Matrigel (Becton-Dickinson) and cells were let to invade
through it. Each experiment was done 3 times in tripli-
cates and measurements represent the average.
For wounding experiments, cells were plated in 24-
well plates and allowed to grow to a confluency of
100%. Experimental wounds were made by dragging a
Gilson plastic yellow pipette tip across the cell culture.
Cultures were then rinsed with PBS and replaced with
fresh culture media. Cell motility was then monitored at
selected time points under the inverted light
microscope.
siRNA Transfection
Cells were transfected with human RhoA, Rac1, Cdc42,
ROCK1 and ROCK2 ONTARGETplus SMART pool
(Dharmacon) composed of four different duplexes (L-
003860-00-0005, L-0035-60-00-0005, L-005057-00-0005,
L-003536-00-0005 and L-004610-00-0005 respectively),
or the siCONTROL RISC-free siRNA (D-001210-03;
Dharmacon) using Invitrogen Lipofectamine™ accord-
ing to the manufacturer’s instructions. The day before
transfection cells were plated into 6-well plates, so that
they reached about 70% confluency the day of transfec-
tion. The amount of siRNA used was 160 pmol for
Cdc42 and Rac1, 80 pmol for RhoA and 32 pmol for
each ROCK1 and ROCK2 were applied in combination.
Treatments with siRNA were replaced every 24 hours
and western blot analysis verified the desired specific
gene silencing 48 hours after transfection.
3D culture
For 3D culture experiments, cells were grown on cover-
slips in 24-well plates in medium with 5 mg/ml Matri-
gel. Briefly, 1 × 10
4 cells were mixed with the Matrigel-
containing medium and a total volume of 300 μlw a s
added in each well in order to form a gel of 1 mm
thickness. Plates were placed in a cell incubator at 37°C
for 1hour, so that gel was formed and 500 μlo fc o m -
plete medium was added on the top of it. Medium was
changed every 2 days and cells left to grow for 12 days.
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and confocal microscopes after the appropriate staining.
Statistical analysis
Data are represented throughout the text with ± Stan-
dard deviation error bars. Statistical significance was
tested with the unpaired Student t-test.
Results
BRAF
V600E induces distinct morphological changes in
colon adenocarcinoma cells as compared to KRAS
G12V
and loss of their epithelial architecture in 3D culture
Previously established Caco-BR cells have adopted a
substantially different morphology when compared to
the parental Caco-2 cells [21]. The elongated morphol-
ogy acquired by Caco-BR cells was characterized by
long membrane protrusions (Figure 1A, Additional Fig-
ure 1). We present evidence that the morphology of
Caco-BR13 cells show properties of both Caco-2 epithe-
lial nature and of the mesenchymal phenotype of Caco-
H2 cells. On the other hand, Caco-K15 cells, which
overexpress KRAS
G12V, have retained the overall paren-
tal morphology of Caco-2 cells. For comparison, estab-
lished adenocarcinoma cell lines HT29 and DLD-1,
bearing mutant BRAF
V600E and KRAS
G13D respectively,
have also been analyzed in the present study. It is of
interest that the phenotype of Caco-BR cells resembles
that of DLD-1 cells (KRAS
G13D), especially since both of
these cell types share high levels of p-BRAF (later ana-
lyzed). Our previous study shows important similarities
between Caco-BR and DLD-1 cells regarding their
tumourigenic properties and signaling pathways, sug-
gesting that their transformation process occurs mainly
through the constitutive activation of the MAPK (Mito-
gen-Activated Protein Kinase) pathway [21]. Staining
with phalloidin resolved the morphological differences
within the cell line panel indicating major actin cytoske-
leton changes (Figure 1A). More specifically, in Caco-
BR13 cells the formation of stress fibers was enhanced,
whereas formation of filopodia-membrane protrusions
enriched with actin- is evident in Caco-K15 cells (Figure
1A-ii, arrow).
In order to study in depth the morphology and archi-
tecture of the different cell lines under conditions that
resemble the real tissue microenvironment, the three-
dimensional (3D) culture system was adopted. As also
previously shown [22], Caco-2 cells were organized into
cyst-like structures that resemble normal colon cell
architecture following their growth in Matrigel for about
12 days (Figure 1B). In contrast, Caco-H cells (EMT
model) formed invasive masses with elongated protru-
sions, an architecture not shared by Caco-BR13 and
Caco-K15 cells (Figure 1B, upper panel, black arrow).
During 3D culture conditions, normal epithelial cells are
organized into spheroids presenting a characteristic cen-
trally-localized hollow lumen and distinct polarization of
cells surrounding this lumen. Epithelial cancer cells do
not form such structures; instead they develop non-
polarized clusters with limited differentiation [23,24].
Following staining with Hoechst and phalloidin the abil-
ity of Caco-2 cells to form spheroids with lumen was
observed, a property also retained by Caco-K15 cells but
completely absent in Caco-BR13 and Caco-H2 cells (Fig-
ure 1B, lower panel). Significantly enlarged and more
compact spheroids without lumen were formed by
Caco-BR13 cells as compared to Caco-2 cells. In the
case of Caco-H2 cells, no typical spheroids were formed,
instead large masses with non-canonical shape were
observed, typical of cancer cells. Therefore, under 2D as
well as 3D culture conditions BRAF
V600E overexpression
managed to alter the morphology of colon adenocarci-
noma cells, rendering them a more mesenchymal-like
phenotype, while KRAS
G12V conserved the epithelial
architecture of Caco-2 cells in general.
BRAF
V600E downregulates E-cadherin at the mRNA level
and impairs its distribution in human colon
adenocarcinoma cells
It has been previously shown that HRAS
G12V converts
Caco-2 epithelial into mesenchymal cells by inducing
loss of E-cadherin and overexpression of vimentin [25].
I no r d e rt oe x a m i n ew h e t h e rB R A F
V600E had a similar
effect on Caco-2 cells, the expression and localization
of E-cadherin was analyzed (Figure 2A, B). Transforma-
tion of Caco-2 cells with BRAF
V600E led to a significant
decrease in the mRNA levels of E-cadherin but had no
significant effect on the actual protein expression (Fig-
ure 2A). Notably, in Caco-BR cells reduced intensity
for E-cadherin was observed mostly in lower molecular
weight protein bands representing the mature protein
at 120 kDa (Figure 2A-lower panel, high exposure),
whereas the decrease in the actual precursors at 135
kDa (Figure 2A-lower panel, low exposure), is consid-
erably less. It appears that mutant BRAF
V600E but not
upstream KRAS
G12V activation is able to suppress the
mature E-cadherin, while the precursor remained
mostly unaffected. Nevertheless, immunostaining with
E-cadherin revealed a significant impairment of its dis-
tribution at the cell-cell boundaries since staining
appeared discontinuous at the adherent junctions (Fig-
ure 2B, upper panel magnification). Expression of E-
cadherin in the Caco-BR grown in 3D spheroids was
found significantly downregulated with diffused distri-
bution (Figure 2B, lower panel). In contrast, the epithe-
lial marker E-cadherin was normally localized at the
cell-cell junctions of Caco-2 and Caco-K15 cells (Fig-
ure 2B, lower panel magnification). In order to deter-
mine whether Caco-BR cells have acquired more
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V600E induces loss of epithelial characteristics of colon adenocarcinoma cells.( A) Confocal images after phalloidin staining
show the altered morphology of Caco-BR13 cells and filopodia formation in Caco-K cells (arrow). Representative confocal images are shown in
high (i) and low (ii) cell density. (B) Light microscope and confocal images of phalloidin staining in 3D cultures illustrates the architecture of
Caco-2 and derived oncogenic models after 12 days of growth in Matrigel. Caco-2 and Caco-K15 cells formed spheroids with the typical lumen
(arrows), a structure completely absent in Caco-BR13 and Caco-H2 cells.
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V600E impairs distribution of E-cadherin.( A) Real-Time PCR (upper panel) and western blot analysis of E-cadherin (lower panel).
(B) Confocal images in 2D (upper panel) and 3D (lower panel) conditions indicate disorganized of E-cadherin localization and its significant
reduction in Caco-BR13 cells. (C) Real-Time PCR (upper panel) and western blot analysis of Vimentin (lower panel). (D) Confocal images of
Vimentin show no alteration of this protein in Caco-BR13 and Caco-2 cells. (E) Real-Time PCR (upper panel) and western blot analysis (lower
panel) for N-cadherin indicates augmentation of this mesenchymal marker in Caco-BR cells. (F) Confocal images of N-cadherin. Indicated
antibodies in the western blot analysis were hybridized on the same membrane and slower migrating band appearing above tubulin represents
Vimentin. Real-Time PCR expression experiments were performed twice in triplicates and representative confocal images are shown.
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the mesenchymal marker Vimentin were examined (Fig-
ure 2C). An increase of about 3-fold was observed at the
protein level, while confocal images did not show signifi-
cant difference, as compared to Caco-2 (Figure 2D), since
it is known that some cancer epithelial cells abnormally
express N-cadherin which has been shown to promote
motility and invasion [26,27], N-cadherin expression was
examined (Figure 2E). In Caco-BR cells N-cadherin
expression is increased about 2-fold both at mRNA and
protein levels, as compared to Caco-2 cells. Confocal
images confirmed this increase, as shown in Figure 2F.
Taken together these data suggest that BRAF
V600E
overexpression failed to induce an integrated
EMT phenotype, which is the case with HRAS
G12V over-
expression [25], but managed to transform Caco-2 cells
through the loss of some important epithelial characteristics.
Differential BRAF
V600E, KRAS
G12V and HRAS
G12V effect on
the migration and invasion ability of Caco-2 cells in vitro
To further explore oncogenic effects on the cell cytoske-
leton with regard to oncogenic transformation, the inva-
sive and migratory properties of the previously
established oncogenic cell models and in colon cancer
cell lines HT29 and DLD-1 were analyzed. Transforma-
tion induced by each of the three oncogenes KRAS
G12V
(Caco-K cells), BRAF
V600E (Caco-BR cells) and HRAS
G12V
(Caco-H cells) managed to increase the ability of Caco-2
cells to migrate and invade in vitro, independently of
their proliferating ability, which has been previously ana-
lyzed in [21]. More specifically, BRAF
V600E and HRAS
G12V
provided Caco-2 cells with highly migrating and invasive
properties, some similar to those in DLD-1 cells (Figure
3A, B), which is compatible with their more elongated
morphology described earlier (Figure 1). Moreover,
Figure 3 KRAS
G12V, BRAF
V600E and HRAS
G12V oncogenic effects on the ability of colon adenocarcinoma cells to migrate and invade in
vitro.( A) Cells were seeded on a polycarbonate membrane and allowed to migrate for 30 hours. Cells that migrated through the surface of the
membrane were stained with crystal violet and counted by bright field microscopy. (B) For the invasion assay cell were seed on polycarbonate
membrane coated with matrigel and incubate for 36 hours. (C) HT29 cells transfected with shRNA-BRAF
V600E (HTshB3) or empty vector (HTps)
and DLD-1 cells before and after knockout of KRAS
G13D (DKO4). Migration assay was performed as mentioned in (A). *: P ≤ 0,05; **: P ≤ 0,01; ***:
P ≤ 0,001 as determined with Student t-test.
Makrodouli et al. Molecular Cancer 2011, 10:118
http://www.molecular-cancer.com/content/10/1/118
Page 8 of 21Caco-K cells, that retained typical epithelial morphology
of Caco-2 parental cells also presented enhanced migrat-
ing and invasive properties, but to a lesser extent. Taken
together, morphological properties induced by either
BRAF
V600E or KRAS
G12V oncogene affected the ability of
Caco-2 cells to migrate and invade in vitro, but were not
sufficient to fully reverse their epithelial phenotype. The
role of BRAF and KRAS oncogenes in altering cytoskele-
tal properties was further emphasized following depletion
of BRAF
V600E by shRNA in HT29 cells, where migration
ability of HT-ShBR3 cells, with downregulated expression
of mtBRAF gene, was significantly impaired as compared
to the empty vector control HT-ps cells. Likewise, knock
out of KRAS
G13D in DLD-1 cells (DKO-4) [28] signifi-
cantly reverted the migration ability of DLD-1 cells (Fig-
ure 3C).
BRAF
V600E enhances the ability of Caco-2 cells to migrate
and invade in vitro through RhoA activation
Overexpression of BRAF
V600E in Caco-2 cells had a pro-
found effect on the RAS effector protein RhoA (Figure
4). In Caco-BR cells activation of RhoA is increased
(Figure 4A) as well as phosphorylation of its down-
stream target Cofilin, a protein that is related to stress
fibre formation (Figure 4B). These findings are closely
related to the observation regarding increased stress
fibre formation indicated by phalloidin staining in Caco-
BR13 cells (Figure 1). Notably, an extra band of lower
molecular weight is detected for RhoA in Caco-BR and
DLD-1 cells, which potentially represents the main
active GTPase form (Figure 4A). A variant of lower
molecular weight for RhoA protein has previously been
reported both in colon and breast tissues [7]. However,
Figure 4 BRAF
V600E enhances the migrating and invasive capacity of colon adenocarcinoma cells through RhoA activation.( A) GST-pull
down assay for RhoA activation and quantification (upper and middle panel) and western blot analysis of pSer
445BRAF levels in a panel of cell
lines (lower panel). (B) Western blot analysis p-Cofilin that is enhanced in Caco-BR13 and Caco-BR23 cells as compared to the parental Caco-2
cells (upper panel) and quantification (lower panel).
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inhibitor MG-132, both in Caco-BR and DLD-1 cells,
suggested no association of this faster migrating RhoA
band with alternative splicing or proteasomal degrada-
tion (data not shown). These data suggested that the
additional band potentially represents a post-transla-
tional modification of RhoA protein. To further explore
t h er o l eo fB R A F
V600E in the activation of the RhoA
pathway, transient transfection of the oncogene in Caco-
2 cells was performed (Additional Figure 2). Subsequent
analysis of the migration and invasion properties showed
that moderate RhoA activation induced a partial cell
migration and cell invasion response (Addition Figure
2A, B). Notably in the invasion assay cell phenotype
became slightly altered and resembled that of the stable
Caco-BR clones (Additional Figure 2C), suggesting that
as t a b l ee x p r e s s i o no fB R A F
V600E is required to achieve
complete cell transformation and extensive RhoA
activation.
Regarding the importance of RhoA activation in the
induced cell migration and invasion observed in Caco-
BR cells, siRNA against RhoA was performed leading to
significant protein depletion in both Caco-2 and Caco-
BR13 cells (Figure 5A). Depletion of RhoA substantially
impaired both acquired properties with more profound
effect in Caco-BR13 cells, further illustrating its central
Figure 5 The impact of depleting RhoA in cell migration and invasion and its regulation by signalling pathways.( A) Caco-2 and Caco-
BR cells treated for 48 hours with 80 pmol of a negative siRNA control sequence (siCtr) or with siRNA against RhoA and analysed by western
blot with indicated antibodies. (B) Cell migration and cell invasion of Caco-2 and Caco-BR13 following siRNA of RhoA. (C) DLD-1 and DKO4 cells
treated with 80 pmol of siRNA against RhoA for 48 hours and analyzed by western blot for RhoA. (upper panel). Cell migration ability was
assayed 48-hour after treatment with siRNA against RhoA (lower panel). (D) HTps, HTshBR3 cells treated with 80 pmol of siRNA against RhoA for
48 hours and analyzed by western blot for RhoA (upper panel). Cell migration ability was assayed 48-hour after treatment with siRNA against
RhoA (lower panel). (E) GST pull-down RhoA activation assay following treatment for 30 minutes with 10 μM of UO126 was performed in Caco-2
and Caco-BR13 cells (upper panel). Levels of p-cofilin and p-Myl were analysed by western blot following treatment with 1 μM wortmanin for
30-120 minutes (lower panel). *: P ≤ 0,05; **: P ≤ 0,01; ***: P ≤ 0,001 as determined with Student t-test.
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V600E oncogene-induced transformation
of colon adenocarcinoma cells (Figure 5B). Moreover,
following RhoA depletion in Caco-2 cells, the number
and size of stress fibres were notably reduced as com-
pared to Caco-BR cells, where no such alteration was
observed (data not shown).
In order to study further the impact of RhoA GTPase
on cell migration, silencing of RhoA was performed in
DLD-1 and HT29 cells. Considering that these cell lines
bear mutation in KRAS
G13D and BRAF
V600E respectively,
RhoA depletion was also performed in selected clones
where KRAS
G13D (DKO4) or BRAF
V600E (HTshBR3) was
knocked out or down regulated via shRNA respectively.
This approach can implement the connection between
each oncogene and the small GTPase. After silencing of
RhoA, cell migration was significantly reduced in DLD-
1, while no reduction was observed in DKO4 cells,
where mutant KRAS
G13D is knocked out, (Figure 5C).
D e p l e t i o no fR h o Ai nH T s h B R 3( t r a n s f e c t e dw i t h
shRNA pSUPER BRAF
V600E) cells with suppressed
BRAF
V600E activity did not reverse the ability of HT29
cell to migrate, while in HTps (HT29 cells transfected
with empty vector pSUPER) a moderate reduction in
cell migration was observed (Figure 5D). Taken
together, these results indicate that both BRAF and
KRAS oncogenes utilize RhoA activation to promote cell
migration.
In a different approach, inhibition of RhoA down-
stream signalling was achieved via treatment of cells
with UO126, a MEK (mitogen-activated protein kinase/
extracellular signal-regulated kinase kinase) inhibitor
targeting the MAPK pathway, which is active in Caco-
BR cells [21]. Treatment with UO126, at the most opti-
mal treatment condition (Additional Figure 3), resulted
in the decreased activation of RhoA illustrating that
mutant BRAF
V600E utilises the MAPK pathway to acti-
vate RhoA (Figure 5E, upper panel). Alternative regula-
tion of RhoA through the PI3K pathway was analysed in
Caco-BR cells, and a mild effect on RhoA downstream
components like p-Cofilin and p-Myl was observed (Fig-
ure 5E, lower panel).
Analysis of RhoA-ROCK axis
Since RhoA appears to be essential for the attained
migration in Caco-BR13 cells, RhoA-Rho kinase signal-
ling was inhibited using the selective ROCK (Rho-asso-
ciated coiled coil forming protein serine/threonine
kinase) inhibitor Y-27632 aiming to inhibit cell migra-
tion. Treatment of Caco-2 and Caco-BR13 cells with the
ROCK inhibitor had a moderate effect on downstream
target p-Cofilin, while cell motility was found signifi-
cantly increased in both cell lines (Figure 6A-B). To
exclude the possibility of this observation being the
non-specific effect of the inhibitor targeting several
other kinases, siRNA against both ROCK isoforms
(ROCK1 and ROCK2) was applied to both Caco-BR
clones and parental Caco-2 cells (Figure 6C). Besides,
the use of siRNA to deplete a protein and especially a
small GTPase can prove more promising since the spe-
cific protein sequence is targeted. In several reported
studies, treatment with a selective inhibitor may produce
more adverse effect through interaction with other
(associated) components. Regardless efficient ROCK
depletion, no inhibition in cell migration or invasion
was observed in BRAF
V600E transformed cells (Figure
6D). Nevertheless increase motility was recorded in
Caco-2 cells suggesting that Rac1 activation may be tak-
ing a lead role in the absence of the RhoA-Rho kinase
signalling.
KRAS
G12V induces Cdc42-dependent migration ability and
filopodia formation in Caco-2 cells, partially dependent
on PI3K pathway
Previous studies have indicated that RhoA, Rac1 and
Cdc42 signalling is essential for oncogenic Ras trans-
forming capacity [29,30]. In the present study, Caco-2
cells overexpressing mutant KRAS
G12V (Caco-K), selec-
tive activation for Cdc42 was detected (Figure 7A). The
formation of filopodia in these cells, earlier described,
was in agreement with the high Cdc42 activity and is
illustrated here by staining with antibody against Fascin,
a filopodia marker (Figure 7B, upper panel). A large
number of relatively short filopodia distributed almost
exclusively at the cell periphery was evident in Caco-K
cells, while Caco-BR and Caco-H cells formed less but
longer structures with a rather polarized shape poten-
tially pointing towards the direction of cell migration
(Figure 7B, upper panel). Nevertheless, no changes in
Fascin protein expression were recorded in the different
cell lines, (Figure 7B, lower panel). Increased migration
ability in Caco-BR and Caco-H cells may be indicative
for the length and the location of filopodia. It has been
previously shown that in CHO-K1 cells (Chinese ham-
ster ovary fibroblast- like cells) RhoA expression down-
regulates Cdc42 and Rac1 activity in order to regulate
membrane protrusions and cell polarity. In addition,
Rac1 activity may down-regulate Cdc42 activity and pro-
mote the formation of stabilized rather than transient
protrusions [31]. Indeed, low Cdc42 activity was
recorded in Caco-BR and Caco-H cells where RhoA sig-
naling is activated. To explore the role of Cdc42 in
mutant KRAS
G12V induced cell transformation, Caco-2
and Caco-K15 cells were treated with siRNA against this
small GTPase. Significant downregulation of Cdc42 at
the protein level was observed in both cell lines (Figure
7C-upper panel), that caused a significant decrease of
cell migration and invasion ability of Caco-K15 and of
Caco-2 cells but to a lesser extent (Figure 7C-lower
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formation, when Caco-K cells were treated with siRNA
against Cdc42 acquired rounded cell membrane lacking
filapodia protrusion suggesting that filopodia formation
in Caco-K cells is Cdc42-dependent (Figure 7D). These
findings suggest that KRAS
G12V regulates motility and
invasiveness of colon cancer cells through the Cdc42
GTPase.
Considering that the PI3K pathway is also a KRAS
effector pathway, the possibility of a cross-talk between
the PI3K signalling pathway and Cdc42 was explored
[16,21]. Following treatment with wortmanin at the
most optimal treatment condition, as retrieved from
inhibition of the active PI3K pathway in Caco-H2 cells
that show high p-AKT levels (Additional Figure 4),
resulted in reduced Cdc42 activity. This illustrates how
Cdc42 activation in response to the KRAS
G12V-PI3K sig-
nalling pathway can be potentially essential for Cdc42-
dependent cell migration and invasion properties (Figure
7E).
HRAS
G12V induces high cell migration and invasion
properties mediated by Rac1 associated with acquired
EMT
Activation of Rac1, another RAS effector protein, was
found slightly increased in Caco-H2 cells with EMT
characteristics [15,25] (Figure 8A). Activation of Rac1 in
Caco-H2 cells is in agreement with previous studies that
correlate Rac1 with EMT and the inhibition of E-cad-
herin in mammary epithelial and pancreatic carcinoma
cells respectively [32]. In contrast, a weak effect on Rac1
GTPase was recorded in Caco-BR cells (Figure 8A) and
could be explained by the known antagonistic effect that
exists between RhoA and Rac1 [33]. As described ear-
lier, HRAS
G12V-transfected Caco-2 cells (Caco-H2) have
undergone EMT, followed by the dramatic reduction of
Figure 6 Inhibition of RhoA-Rho kinase pathway in Caco-2 and Caco-BR cells.( A) Caco-2 and Caco-BR13 cells were treated with the Rho
kinase inhibitor Y-27632 for 4 hours at indicated concentrations to achieve downregulation of p-Cofilin. (B) The effect of Y-27632 on cell
migration in Caco-2 and Caco-BR cells. ***: P ≤ 0,001, as determined with Student t-test. (C) Cells were treated for 48 hours with 64 pmol of a
negative siRNA control sequence (siCtr) or with 32 pmol siRNA against ROCK1 combined with 32 pmol against ROCK2. (D) Cell migration and
invasion was determined following treatment with siRNA against ROCK1/2.
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G12V enhances migrating and invasive capacity of colon adenocarcinoma cells through Cdc42 activation.( A)G S T - p u l l
down assay for Cdc42 activation in a panel of cell lines and quantification. (B) Fascin confocal staining illustrates filopodia formation (upper
panel) and western blot analysis for expression of fascin and quantification (lower panel). (C) Caco-2 and Caco-K15 cells were treated for 48
hours with 160 pmol of a negative control siRNA sequence (siCtr) or with Cdc42-specific siRNA analyzed by western blot (upper panel).
Assesment of cell migration and invasion in Caco-2 and Caco-K15 cells following siRNA against Cdc42 for 48 hours (lower panel). (D) Confocal
images of Fascin in Caco-K cells after treatment with siRNA against Cdc42. (E) GST pull-down assay for Cdc42 activation in Caco-2 and Caco-K15
cells following treatment for 30 minutes with 1 μM PI3K inhibitor wortmanin. Results of migration and invasion assays were consistent between
3 independent experiments performed in triplicates. ***: P ≤ 0,001 as determined with Student t-test.
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depletion using the specific inhibitor wortmanin at the
most optimal treatment condition (Additional Figure 4),
Rac1 activity was successfully inhibited only in Caco-2
cells, leaving Caco-H2 cells unaffected (Figure 8B, upper
panel). Notably, under the same treatment conditions
RhoA activity was found to be slightly increased, sug-
gesting an involvement of the PI3K pathway in RhoA
regulation (Figure 8B, lower panel). It is therefore con-
cluded that in Caco-H2 cells, HRAS
G12V deregulates
PI3K-dependent activation of Rac1 as well as mediates
RhoA inhibition. To further explore the involvement of
Rac1 activation in the transforming ability of HRAS
G12V
in Caco-2 cells, pharmacological inhibition of Rac1 was
established using the selective inhibitor NSC23766 (Fig-
ure 8C) [34]. Inhibition of Rac1 not only managed to
Figure 8 Rac1 is important for cell migration and invasion properties of Caco-H cells.( A) GST-pull down assay for Rac1 activation in a
panel of cell lines (left panel) and quantification (right panel). (B) Caco-2 and Caco-H2 cells were treated with 1 μM PI3K inhibitor wortmanin for
30 minutes and GST pull-down assay for Rac1 activity (upper panel) and RhoA activity (lower panel) was performed. (C) Caco-H2 cells were
treated with Rac1 specific inhibitor NSC23766 for 36 hours at indicated concentrations after which a GST-pull down assay for Rac1 activation was
performed. (D) Cell migration and invasion ability of Caco-H2 cell in the presence of Rac1 inhibitor NSC23766 was estimated after 36 hours
(upper panel) and quantification.(lower panel) *: P ≤ 0,05 as determined with Student t-test.
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tion and invasion properties in a dose dependent man-
ner (Figure 8D), indicating the critical role of Rac1 in
EMT cell properties of Caco-H cells.
TGFb-1 co-operates with BRAF
V600E and KRAS
G12V
oncogenes to provide Caco-2 cells with enhanced
transformation properties
Since BRAF
V600E and KRAS
G12V oncogenes did not man-
age to fully transform Caco-2 cells nor induced an EMT
phenotype, as HRAS
G12V did, it was further investigated
whether co-operation of oncogene-growth factor can
produce synergistic effect. The previously established
oncogenic models of BRAF
V600E and KRAS
G12V along
with the parental Caco-2 cells were treated with Trans-
forming Growth Factor beta-1 (TGFb-1) for 14 days.
Staining with phalloidin revealed significant morphologi-
cal changes in TGFb-1 treated Caco-K15 cells that were
not observed in Caco-2 cells following treatment with
TGFb-1, while no morphological changes were recorded
in TGFb-1 treated Caco-BR13 cells (Figure 9A). Protein
analysis for E-cadherin, in fractionized soluble (intracel-
lular) and insoluble (bound-membrane E-cadherin)
extracts indicated a reduction of E-cadherin in the inso-
luble fraction in Caco-2 and Caco-K15 cells to a greater
extend (Figure 9B, upper panel). Interestingly, even
though levels of E-cadherin were not altered in Caco-
BR13 cells, confocal images clearly presented disrupted
cell-cell contacts and discontinuous staining which
weakens cell junctions allowing cell migration (Figure
9B, lower panel-arrows). Altered localization of E-cad-
herin is an important mechanism contributing to cell
metastasis [35].
TGFb-1 was also investigated for its potential effect on
cell migration and invasion. Treatment with TGFb-1
increased the capacity of Caco-BR13 cells to invade in
vitro, while no effect in the migrating ability of these
cells was recorded (Figure 9C). This enhanced invasive
capacity of Caco-BR13 cells is independent of their cell
proliferation (Additional Figure 5). In contrast, cell
migration and invasion of Caco-2 and Caco-K15 cells
were not affected by TGFb-1 treatment, although
KRAS
G12V-transfected cells acquired a more elongated
morphology and slightly downregulated E-cadherin.
Taken together, these results suggest that TGFb-1 can
synergise with KRAS
G12V and BRAF
V600E oncogenes to
p r o v i d eC a c o - 2c e l l sw i t ham o r et r a n s f o r m i n g
phenotype.
According to previous studies, the mutation in the C-
terminal domain of Smad4, D351H, that is present in
Caco-2 cells, results in complete Smad4 inactivation
[36]. However, TGFb-1 has been shown to act through
alternative non-Smad pathways, such as Rho GTPases
and MAPK [37-39]. Indeed, following TGFb-1
treatment, enhanced activity for RhoA GTPase as well
as pERK1/2 was recorded in Caco-2, Caco-K15 and
Caco-BR13 cells. Based on these observations other than
non-Smad signaling like RhoA GTPase and pERK1/2
pathways can be regulated by TGF-beta, to induce the
morphological changes observed in the Caco-2 trans-
formed and parental cells (Figure 9D).
Discussion
BRAF
V600E, KRAS
G12V and HRAS
G12V oncogenes
differentially modify morphology and epithelial
characteristics of Caco-2 cells
As presented in this study, the three oncogenes induce
different changes on cell morphology. Specifically,
BRAF
V600E alters the typical epithelial morphology of
Caco-2 cells, the distribution of E-cadherin and reduces
its expression at the mRNA level. The elongated mor-
phology that Caco-BR cells acquired lies between the
epithelial of Caco-2 and the mesenchymal of
HRAS
G12V-transfected cells (Caco-H). However, the
exact mechanism of this effect needs to be further inves-
tigated. There is evidence that Rho GTPases play role in
regulation of E-cadherin. More specifically, active forms
of Rac1 and Cdc42 have a positive effect on E-cadherin
mediated cell-cell adhesions, while RhoA may also parti-
cipate to a lesser extent [40]. On the other hand,
KRAS
G12V does not alter the epithelial phenotype of the
cells, but induces increased number of filopodia, actin
rich finger-like protrusions, that are important for cell
polarity and the direction of cell movement [41].
Regarding HRAS
G12V, EMT cells (Caco-H) have an inva-
sive morphology, well illustrated both in 2D and 3D cell
culture conditions and loss of E-cadherin expression. It
has been established that E-cadherin expression can be
downregulated in epithelial tumours by a number of
mechanisms related to the induction of EMT [42,43]. In
this study, BRAF
V600E has provided Caco-2 cells with
altered epithelial morphology and high migrating and
invading capacity. High vimentin expression is not
detected in Caco-BR cells, like in Caco-H with EMT
characteristics. Instead, Caco-BR cells over-express
another mesenchymal marker, N-cadherin. Taken
together these data suggest that BRAF
V600E is able to
relax cell-cell junctions by reducing E-cadherin expres-
sion and may drive colon epithelial cells to a more
aggressive phenotype, while KRAS
G12V reserves their
epithelial characteristics.
The doubling time and the cell cycle distribution by
means of flow cytometry for each oncogene has been
already described [21]. The increased proliferation rate
of transformed cells may influence cell invasion, but
this could not be the only reason for the enhanced
invasive ability. Here we show that small GTPase path-
ways regulate cell migration and invasion, which do
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tem. More specifically, HRAS
G12V induces high prolif-
eration rates as well as very aggressive cell migration
and invasion properties associated with EMT pheno-
type; BRAF
V600E provides maternal cells with
increased proliferation and with enhanced migration
properties; KRAS
G12V despite the fact that does not
substantially alter cell growth and proliferation, pro-
vides Caco-2 cells with increased filopodia formation
and enhanced migration properties.
Figure 9 TGFb-1 enhances the transforming properties by BRAF
V600E and KRAS
G12V oncogenes.( A) Confocal images of phalloidin staining
after 14 days of TGFb-1 treatment illustrate a more transforming phenotype acquired by Caco-K15 cells. Representative confocal images are
shown in low (i) and high (ii) cell density. (B) Western blot analysis of E-cadherin in soluble and insoluble cell fractions (upper panel) and
confocal images (lower panel) after 14 days of TGFb-1 treatment. Fragmentation of E-cadherin in Caco-BR13 cells is indicated by arrows. (C)
Assessment of cell migration and invasion of Caco-2, Caco-BR13 and Caco-K15 cells during TGFb-1 treatment for 14 days. (D) Effect of TGFb-1 in
RhoA activation and ERK1/2 phosphorylation. Caco-2, Caco-BR13 and Caco-K15 cells were serum starved overnight and treated with 5 ng/ml
TGFb-1 for 5 and 15 minutes after which a GST pull-down RhoA activation assay was performed.
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V600E, KRAS
G12V and HRAS
G12V enhance migrating
and invading capacity of Caco-2 cells, through different
Rho pathway
The three oncogenes BRAF
V600E,K R A S
G12V and
HRAS
G12V managed to enhance migrating and invading
capacity of Caco-2 cells, but to a different extent, with
HRAS
G12V being more efficient. These cell properties
seem to be dependent of cell morphology, since Caco-
BR and Caco-H cells that are more elongated show high
migration and invasion as compared to epithelial Caco-2
and Caco-K cells. Moreover, the three oncogenes also
differ concerning the activation of individual Rho path-
way responsible for cell migration and invasion. RhoA
GTPase is highly activated in Caco-BR cells, resulting in
their increased ability to migrate and invade in vitro.S o
far, little is known about the exact correlation between
RAF kinases and Rho GTPases and their impact on
human cancer progression. Two previous studies have
shown cooperation between RAF and RhoA in epithelial
cell transformation and in melanoma progression. More
specifically, constitutive active Raf-1 and RhoA coop-
erate in order to transform rat intestinal epithelial cells,
providing them with a spindle-like morphology, ancho-
rage independent growth and capacity to form tumours
i na t h y m i cn u d em i c e[ 4 4 ] .I no u rs y s t e m ,BRAF
V600E
induces constitutively high pRaf-1 levels and provides
Caco-2 cells with new characteristics, including spindle-
like morphology, anchorage independent growth and
capacity to form tumours in athymic nude mice, albeit
through high levels of pBRAF and pRaf-1 [21]. In a dif-
ferent study, human metastatic melanoma cells were
treated with siRNA against BRAF
V600E and S-phase
kinase-associated protein-2 (Skp-2), a positive regulator
of RhoA, which resulted in both cell migration and inva-
sion inhibition, suggesting that the BRAF-MAPK path-
way and Skp-2-RhoA cascade can contribute to the
invasive nature of melanoma [45]. A more recent study
revealed that TGF-b-mediated activation of RhoA is
required for efficient BRAF
V600E transformation of
NIH3T3 cells [37]. Herein, we present for the first time
that BRAF
V600E-induced ability of human colon epithe-
lial adenocarcinoma cells to migrate and invade in vitro
is mediated by RhoA pathway.
In the case of KRAS
G12V transformed cells (Caco-K)
as indicated from data presented here, the three small
GTPases (RhoA, Rac1 and Cdc42) are differentially acti-
vated. Towards this end, KRAS
G12V-transfected cells
present increased number of filopodia, actin reach fin-
ger-like protrusions, that are regulated by Cdc42
GTPase [41] and are important for cell polarity, as well
as for the direction of cell movement. In contrast to
BRAF oncogene, RAS has been widely studied concern-
ing its cooperation with Rho GTPases in cancer progres-
sion. Targeted silencing of Cdc42 exhibited the
importance of this GTPase in motility and invasion of
Caco-K cells, suggesting that KRAS
G12V induces migra-
tion and invasion properties in human colon cancer
cells through activation of Cdc42.
Regarding HRAS
G12V, it is evident that Rac1 plays an
important role in EMT properties of Caco-H cells, since
inhibition of this GTPase with specific inhibitor, resulted
in decreased capacity of the cells to migrate and invade
in vitro. It is worth mentioning that inhibition of Rac1
was also attempted using specific siRNA, but downregu-
lation of Rac1 was not signi f i c a n t( d a t an o ts h o w n ) .
Although activation of Rac1 in Caco-H cells is moder-
ate, as compared to Caco-2, activity of RhoA is reduced,
potentially due to antagonistic action of RhoA and Rac1
in actin cytoskeleton organization [46].
Regulation of Rho GTPases pathway differs in each case
of oncogene transformation
a. BRAF
V600E and RhoA
In our system, cross talk between BRAF
V600E and RhoA is
mainly mediated through MEK-ERK pathway, as indi-
cated by cell treatment with a MEK inhibitor. Additional
data which link BRAF
V600E to Rho signalling were
recently derived from microarray analysis preformed with
Caco-BR cells in our lab (Joyce T., et al., Under Revision).
Global gene expression analysis revealed that RhoA-spe-
cific guanine nucleotide exchange factors (GEFs), like
GEF11 (PDZ-RhoGEF) and GEF18 (p114-rhoGEF)
[47,48] were upregulated in Caco-BR cells. This indicates
that mutant BRAF can positively regulate RhoA activity
by modulating the expression of its regulatory factors.
Remarkably, as presented in a recent study, ERK can pro-
mote Rho dependent focal adhesion formation by sup-
pressing p190A RhoGAP [49]. Nevertheless, in our
system RhoA-ROCK axis does not appear to play crucial
role in the enhanced cell migration and invasion proper-
ties, since inhibition of ROCK does not alter the capacity
of Caco-BR cells to migrate and invade in vitro.I na g r e e -
ment with this data, previous studies have shown that
treatment of human endometrial stromal cells (hESCs)
and NIH 3T3 mouse fibroblasts with ROCK inhibitor Y-
27632 resulted in enhanced cell motility [50,51]. A possi-
ble explanation may be the fact that RhoA has alternative
effectors, such as Dia1 which was shown to be involved
in RhoA-dependent cytoskeletal properties. In human
colon cancer cells Dia1 can act downstream of RhoA to
regulate the actin network [52]. Previous studies using
HeLa or breast cancer cells showed that active RhoA is
required for the induction of membrane ruffles in migrat-
ing cells also mediated by Dia1 and not ROCK [52,53].
Here, active RhoA may potentially act mainly through
Dia1 and not ROCK to induce migration and invasion in
Caco-BR cells and for that reason downregulation of
ROCK may not affect these cell properties.
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means of selective siRNA revealed that RhoA may have
an antagonistic function with Cdc42 in Caco-BR13 cells
(Additional Figure 6A). This can be achieved though
competition for common regulatory molecules, like Rho
guanine nucleotide dissociation inhibitors (RhoGDIs)
[54]. Based on these findings, a working model is pro-
posed for BRAF
V600E-induced invasive phenotype (Fig-
ure 10B): BAF
V600E induces MEK activation, which in
turn activates RhoA most likely through specific GEFs
and GAPs. In BRAF
V600E-transformed cells, RhoA antag-
onises with Cdc42 through competition for common
regulatory molecules. At the same time, E-cadherin is
downregulated, resulting in the relaxation of cell-cell
adhesion and increased migratory and invasive capacity.
BRAF
V600E induced transforming properties are further
enhanced through cooperation with TGFb-1, suggesting
that synergism between oncogene and growth factor is
essential for induction of further migration properties in
colon adenocarcinoma cells. Since Smad pathway is not
functional in this cell system, due to an intrinsic muta-
tion on Smad4 in Caco-2 cells, activation of RhoA in
response to TGFb-1 treatment, can potentially mediate
the induced cell properties by TGFb-1 related to EMT.
b. K-RAS, Cdc42 and PI3K pathway
In Caco-K cells, PI3K pathway is important for regula-
tion of Cdc42 activity, as shown by treatment by specific
PI3K inhibitors. According to another study, PI3K/
Cdc42 and PI3K/Rac1 pathways are important in LPA-
mediated migration of glioma cells [55]. Moreover,
results from microarray analysis showed that in Caco-K
cells Asef2, a guanine nucleotide exchange factor speci-
fic for Rac1 and Cdc42 is highly overexpressed (unpub-
lished data). Remarkably, Cdc42 regulates Rac1
expression in KRAS
G12V stably expressing cells, since
decreasing Cdc42 expression by specific siRNA results
in downregulation of Rac1 in Caco-K15 cells (Additional
Figure 6B). In a summarized model, downstream effec-
tors of RAS constitutively active in response to
KRAS
G12V, such as PI3K or AKT, lead to activation of
Cdc42 and Rac1 through specific GEFs. Active GTPase
induces filopodia and lamellipodia formation that contri-
bute in migration and invasion ability of the cells (Fig-
ure 10C). Although KRAS
G12V does not alter
substantially the epithelial morphology of Caco-2 cells,
its cooperation with TGFb- 1i n d u c e sam o r ea g g r e s s i v e
phenotype indicating that this oncogene needs the con-
tribution of a growth factor to accomplish cell transfor-
mation. Interestingly, mutant KRAS oncogene co-
operates with TGFb-1 to induce target genes like
SNAIL, which regulates expression of E-cadherin in sev-
eral systems (data not shown).
c. Ha-RAS and Rac1
In the case of HRAS
G12V, previous studies involving
Caco-H2 cells have shown that MAPK, PI3K and JUN
N-terminal kinase (JNK) pathways are highly activated
as compared to parental Caco-2 cells [16,25]. Similarly,
in the MCF10A breast cancer cell line HRAS activates
PI3K pathway through Rac1 resulting in invasive pheno-
type [56]. Inhibition of MAPK but not Rac1 restored E-
cadherin junctions and epithelial morphology in
HRAS
D12-transfected cells [57]. Furthermore, the role of
Figure 10 Proposed models for BRAF
V600E, KRAS
G12V and HRAS
G12V (EMT) - induced cytoskeletal changes in colon cells.( A)W i l dt y p e
RAS and BRAF regulate RhoA and Rac1; (B) BRAF
V600E regulates RhoA; (C) KRAS
G12V regulates Cdc42; (D) Implication of Rac1 signaling in
HRAS
G12V- induced EMT.
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tumour cells was investigated and showed that domi-
nant negative Rac1 reduces migration, invasion and
tumour growth through inhibition of MAPK signalling
[58], while more recently, it was established that FAK
signalling is required for TGFbeta-mediated EMT in
hepatocytes [21]. In this study evidence is provided that
FAK is up-regulated in Caco-H2 cells, like in invasive
tumours and that Y397 phosphorylation is reduced in
these cells (additional Figure 7). A previous study has
shown that activated RAS induces dephosphorylation
and inhibition of FAK, mediated by Fgd1-Cdc42-PAK1-
MEK-ERK signaling cascade. This inhibition of FAK
mediated by this signal promotes Ras-induced cell
migration, invasion, and metastasis [59]. Taken together,
am o d e lf o rH R A S
G12V-i n d u c e dE M Ti sp r o p o s e di n
human colon cells (Figure 10D): mutant HRAS exerts
its function through different pathways (MAPK, PI3K)
and induces PI3K dependent Rac1 activation and
expression of other EMT-mediators to contribute in
EMT phenotype and related properties. Downstream of
these pathways other molecules also implicated in EMT,
like vimentin and integrin a6, have been shown to play
a role in migration properties of these cells through a
Jun/Fra1/AP-1 (activator protein-1)-dependent regula-
tion [25,60,61].
Conclusion
This study shows for the first time that BRAF and RAS
oncogenes utilise different Rho signalling pathways to
induce migration and invasion properties in human
colon adenocarcinoma cells. BRAF
V600E provides human
colon adenocarcinoma cells with a more “aggressive”
phenotype and consequential migrating and invading
properties, mainly through RhoA activation, regulated by
MEK pathway. KRAS
G12V utilizes Cdc42 in order to
enhance cell migration and filopodia formation, while
Rac1 GTPase plays important role in HRAS
G12V-induced
EMT characteristics, both at least partially dependent on
PI3K pathway. Moreover, BRAF and KRAS oncogenes
cooperate with TGFb-1 pathway to provide cells with
additional transforming properties. Findings and cell
models proposed here may provide useful tools for future
studies that will focus on further dissection of specific
oncogene induced signalling pathways. This can be later
exploited toward the design of colon cancer therapeutics
targeting specific Rho pathways based on the oncogenic
mutations found in each patient.
Additional material
Additional file 1: Additional Figure 1. Light microscope photographs
of Caco-2, Caco-BR, Caco-K, Caco-H, HT29 and DLD-1 cells show the
differences in their morphology.
Additional file 2: Additional Figure 2. (A) Transient transfection of
BRAF
V600E in Caco-2 cells by calcium phosphate followed by a GST-pull
down RhoA activation assay. (B) Moderate effects of BRAF
V600E following
transient transfection in Caco-2 cells with respect to the cell migration
and invasion. (C) Arrows indicate polycarbonate membrane pore empty
or occupied by cells in process of migrating or invading through.
Additional file 3: Additional Figure 3. Caco-BR13 cells were treated
with MEK inhibitor UO126 for 30 and 60 minutes at indicated
concentrations to determine optimal conditions.
Additional file 4: Additional Figure 4. Caco-H2 cell were treated with
the PI3K inhibitor wortmanin for 30 and 60 minutes at indicated
concentrations to determine optimal conditions.
Additional file 5: Additional Figure 5. Cell proliferation of Caco-2,
Caco-BR and Caco-K cells following TGFb-1 treatment for 6 days, TGFb-1
was refreshed every 2 days.
Additional file 6: Additional Figure 6. Cross-talk of Rho GTPaes. (A)
Caco-BR13 cells were treated with 80pmol siRNA for RhoA for 48 hours
and GST pull-down assay was performed to examine the effect on Cdc42
activity. (B) Caco-K15 cells were treated with 160pmol siRNA for Cdc42
for 48 hours and expression levels of Rac1 were tested. (C) Caco-H2 cells
were treated with 160pmol of Rac1 specific siRNA and the expression
levels of RhoA were examined.
Additional file 7: Additional Figure 7. Western blot analysis of FAK and
pFak (Y397) (upper panel) and confocal images showing focal adhesions
in Caco-2, Caco-BR Caco-K and Caco-H cells after staining with antibody
against FAK. Representative images are shown.
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